Meiji
Profile
Meiji Holdings (Japan) is a global food-and-pharmaceuticals group (“healthy value” across food, dairy/probiotics, and medicines/vaccines). Core products include functional/probiotic yogurts such as Meiji Probio Yogurt R-1 and LG21, plus dairy drinks, chocolate/cocoa and infant/nutrition and B2B food solutions; in pharmaceuticals it covers influenza vaccines and stable-supply drugs. Meiji Holdings was established April 1, 2009 (as the parent of Meiji Seika Kaisha and Meiji Dairies) and is headquartered at 2-4-16 Kyobashi, Chuo-ku, Tokyo. It is listed on the Tokyo Stock Exchange Prime Market (code 2269). Scale: FY2025 net sales were JPY 1,155,179 million (FYE March 2025) with Food JPY 925.5bn (80.1%) and Pharmaceuticals JPY 229.6bn (19.9%); employees (consolidated) 17,231 as of Mar 31, 2025. Key “technology” is proprietary nutrition/profiling systems (Meiji NPS) and health/product differentiation via proprietary manufacturing/technology (e.g., R-1; also patent-filed yogurt manufacturing for a new brand). Latest developments in 2025–2026: 2026 Medium-Term Business Plan runs FY2025–FY2027 with actions including closing the Tohoku plant in H2 FY2025, expanding overseas (notably China/US) and B2B, and launching new items (e.g., Meiji W skincare yogurt in Mar 2025, Meiji Nyuu Healthy Bottle in Apr 2025, and Meiji Nama no Toki with a patent-filed manufacturing method in May 2025). The company is active.
Sources#
- Corporate Profile
- Investor FAQ | Meiji Group
- Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2026 [Based on Japanese GAAP]
- Worldwide Locations | Meiji Group
- Invest in Meiji | Meiji Group
- Financial Results for FYE March 2025 (FY2024)
- 2026 Medium-term Business Plan | Meiji Group
- About Meiji | Meiji Group
- Industry
- Cosmetics, Food ingredients, Veterinary
- Topics
- Probiotics & cultures
- Role
- Research / RTO — “…aboration with universities/research institutes, and investment in startups to create new technologies and bus…”
Bio-solutions it supplies 0
Not yet cited as a supplier in a graded solution.
What they offer
Subsidiaries: 株式会社 明治 (Meiji Co., Ltd.) · Meiji Seika ファルマ株式会社 (Meiji Seika Pharma Co., Ltd.) · ＫＭバイオロジクス株式会社 (KM Biologics Co., Ltd.)
News & status 6
- 2026-12 Latest status: Meiji Holdings announced the transfer of its milk and yogurt businesses and B2B business in China to Shanghai AustAsia Food Co., Ltd., scheduled for completion on December 31, 2026. ↗ ↗ ↗
- 2026-09-24 Meiji Holdings signs Ghana cocoa accords at chocolate centenary event | IBTimes JPMeiji Holdings is expanding its long-standing Ghana cocoa partnership into broader development and wellness initiatives, including sustainable farming, cocoa-byproduct bioplastics, nutrition and health programs, and support for Ghanaian athletes, while …
- 2026-10-04 Meiji University returns Indigenous remains kept on campus to Alaska - The MainichiMeiji University voluntarily returned Indigenous remains that had been kept on its campus since the 1960s, after uncovering the issue in 2021 and coordinating with Alaska Indigenous communities; the case marks the first known instance in Japan of a university …
- 2026-03-30 Japan's Meiji Seika Pharma invests in Centivax to develop next-gen universal vaccine platformMeiji Seika Pharma is making a strategic investment in Centivax to accelerate the development of a next-generation universal vaccine platform, signaling its commitment to expanding into broad, durable immunology programs beyond traditional vaccines.
- 2026-08-25 Meiji Seika to push new vaccine with SII in India - The Times of IndiaMeiji Seika Pharma is expanding via its Indian subsidiary Medreich, eyeing inorganic growth and more generics, while partnering with Serum Institute of India to launch a low-cost Japanese Encephalitis vaccine in India and potentially for exports.
- 2025-09-22 Japan focus: Suntory, Meiji, Otsuka Pharma and more - Alo Japan | AloJapan.comMeiji is expanding its product line by adding NMN to its Amino Collagen powder to boost global market share, and it emphasizes that protein intake—not just exercise—is key for muscle growth, citing NMN/collagen as a strong consumer-focused ingredient strategy.
- 2026-08-24 Piyush Goyal woos Japan's Sumitomo, Meiji Seika for India investment | Asianet NewsableMeiji Seika Pharma is positioned to deepen cooperation with India, expanding its manufacturing and R&D footprint in India as part of broader India–Japan pharmaceutical collaboration.
Network: owners, partners, peers
Ownership & investors 3
| subsidiary | 株式会社 明治 |
| subsidiary | Meiji Seika ファルマ株式会社 |
| subsidiary | KMバイオロジクス株式会社 |
Partners & deals 2
| counterparty | Shanghai AustAsia Food Co …Meiji Holdings announced the transfer of its milk and yogurt businesses and B2B business in China to Shanghai AustAsia Food Co., Ltd., scheduled for completion on December 31, 2026.… |
| counterparty | Ltd …Meiji Holdings announced the transfer of its milk and yogurt businesses and B2B business in China to Shanghai AustAsia Food Co., Ltd., scheduled for completion on December 31, 2026.… |
Similar companies
Yakult Honsha Co., Ltd. · Morinaga Milk Industry · PT Mengniu Diary Indonesia (Yoyic) · PT Yakult Indonesia Persada · Yakult Danone India Pvt ltd · Yakult Malaysia · Yakult Europe B.V. · Yakult Australia Pty. Ltd.
Identity & contacts
Contacts, people and legal identity are available to members.
Sign in as a member